170 related articles for article (PubMed ID: 20046930)
1. The SLIM Study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia.
Knopp RH; Retzlaff BM; Fish B; Dowdy A; Twaddell B; Nguyen T; Paramsothy P
J Clin Lipidol; 2009; 3(3):167-178. PubMed ID: 20046930
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
McKenney JM; McCormick LS; Weiss S; Koren M; Kafonek S; Black DM
Am J Med; 1998 Feb; 104(2):137-43. PubMed ID: 9528731
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (probe) trial.
Bevilacqua M; Guazzini B; Righini V; Barrella M; Toscano R; Chebat E
Curr Ther Res Clin Exp; 2004 Jul; 65(4):330-44. PubMed ID: 24672088
[TBL] [Abstract][Full Text] [Related]
5. Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease.
Moore A; Phan BA; Challender C; Williamson J; Marcovina S; Zhao XQ
J Clin Lipidol; 2007 Dec; 1(6):620-5. PubMed ID: 21291704
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
7. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
[TBL] [Abstract][Full Text] [Related]
8. Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
Insull W; Toth PP; Superko HR; Thakkar RB; Krause S; Jiang P; Parreno RA; Padley RJ
Vasc Health Risk Manag; 2010 Nov; 6():1065-75. PubMed ID: 21191426
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
McKenney JM; Jones PH; Bays HE; Knopp RH; Kashyap ML; Ruoff GE; McGovern ME
Atherosclerosis; 2007 Jun; 192(2):432-7. PubMed ID: 17239888
[TBL] [Abstract][Full Text] [Related]
10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
11. N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.
Dogay Us G; Mushtaq S
Lipids Health Dis; 2022 Sep; 21(1):84. PubMed ID: 36050695
[TBL] [Abstract][Full Text] [Related]
12. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
Alrasadi K; Awan Z; Alwaili K; Ruel I; Hafiane A; Krimbou L; Genest J
Am J Cardiol; 2008 Nov; 102(10):1341-7. PubMed ID: 18993152
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
Capuzzi DM; Morgan JM; Weiss RJ; Chitra RR; Hutchinson HG; Cressman MD
Am J Cardiol; 2003 Jun; 91(11):1304-10. PubMed ID: 12767421
[TBL] [Abstract][Full Text] [Related]
14. A six-month, multicenter, open-label, noncomparative, prospective, observational study of the efficacy and tolerability of atorvastatin in the primary care setting(estudio del control de las hiperlipidemiasen atención primaria): the cheap study.
Gómez-Gerique JA; Alvarez-Sala LA; Armada B; Fernández-Arias I; Martinez J; Hernández G;
Curr Ther Res Clin Exp; 2003 Jun; 64(6):338-54. PubMed ID: 24944383
[TBL] [Abstract][Full Text] [Related]
15. Lipid and transaminase concentrations after formulary conversion of Niaspan to Slo-Niacin.
Byrd C; Mowrey KA
Am J Health Syst Pharm; 2010 Dec; 67(23):2038-42. PubMed ID: 21098376
[TBL] [Abstract][Full Text] [Related]
16. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE
J Am Coll Cardiol; 2013 Oct; 62(17):1580-4. PubMed ID: 23916935
[TBL] [Abstract][Full Text] [Related]
17. Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.
Toth PP; Thakker KM; Jiang P; Padley RJ
Vasc Health Risk Manag; 2012; 8():39-44. PubMed ID: 22323895
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
19. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
Hunninghake DB; Ballantyne CM; Maccubbin DL; Shah AK; Gumbiner B; Mitchel YB
Clin Ther; 2003 Jun; 25(6):1670-86. PubMed ID: 12860491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
